Amgen Newsroom

These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Extensively

Simply Wall StJan 4 09:08 ET

Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz

Kevin TraversJan 3 16:19 ET

Friday? More Like Grinch Day | Wall Street Today

Kevin TraversJan 3 16:02 ET

Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer

Seeking AlphaJan 3 11:21 ET

Santa Claus Came Without Rallying the Troops | Live Stock

Kevin TraversJan 3 10:45 ET

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

BenzingaJan 3 07:39 ET

CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.

CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides

Sina Hong Kong StocksJan 3 03:36 ET

Piper Sandler Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $310

Moomoo NewsJan 2 07:32 ET · Ratings

Amgen Is Maintained at Overweight by Piper Sandler

Dow JonesJan 2 07:01 ET · Ratings

Analyst Expectations For Amgen's Future

BenzingaJan 2 07:00 ET

Amgen Analyst Ratings

BenzingaJan 2 06:48 ET · Ratings

Express News | Amgen Inc : Piper Sandler Cuts Target Price to $310 From $344

ReutersJan 2 00:13 ET

Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025

BenzingaDec 31, 2024 10:45 ET

Express News | UK's Mhra: Tarlatamab Approved to Treat Adult Patients With Small Cell Lung Cancer

ReutersDec 31, 2024 09:09 ET

These Are the Best and Worst Stocks This Year -- Barrons.com

Barron'sDec 31, 2024 08:56 ET

This Biotech Is One of the S&P 500's Worst Performers. It Looks Too Cheap. -- Barrons.com

Barron'sDec 31, 2024 00:01 ET

Is Amgen Inc. (AMGN) the Best Pharma Dividend Stock to Buy In 2024?

Yahoo FinanceDec 30, 2024 16:36 ET

Dow's Nearly 225-Point Drop Led By Losses In Nike, Boeing Stocks

MarketWatchDec 30, 2024 15:22 ET

Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock

Kevin TraversDec 30, 2024 11:01 ET

Weekly Buzz: So far, Santa is Letting us Down

Kevin TraversDec 27, 2024 16:59 ET